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Melatonin madness is everywhere! The media attention 
that melatonin has received recently is truly remarkable 
and has elevated the hormone to cult status. Is all this 
excitement really justified, or is it just hype? What does 
melatonin actually do? Does it signal through specific 
receptors like other hormones? What is its true therapeu- 
tic potential? This minireview addresses these questions 
and highlights recent discoveries that increase our un- 
derstanding of the cellular and molecular actions of this 
hormone. 
Melatonin is the principal hormone of the vertebrate pi- 
neal gland. Pineal melatonin production exhibits astriking 
circadian rhythm that is reflected in circulating melatonin 
levels. In mammals, the melatonin rhythm is generated by 
a master circadian clock in the suprachiasmatic nucleus 
(SCN) of the hypothalamus. The SCN is synchronized (en- 
trained) to the 24 hr day by the daily light-dark cycle, with 
light signaling through adirect retinal pathwayto SCN. The 
SCN clock sends circadian signals over a multisynaptic 
neural pathway to the pineal gland, driving rhythmic mela- 
tonin production. Within the pineal gland, melatonin is syn- 
thesized from serotonin (5-hydroxytryptamine [5-HT]). The 
rate-limiting step in melatonin production is the N-acetyla- 
tion of 5-HT by arylalkylamine N-acetyltransferase (AA- 
NAT), an enzyme whose cDNA has been recently cloned 
(Coon et al., 1995). The AA-NAT rhythm is under SCN 
control, with the resulting melatonin rhythm distinguished 
by high levels at night in all vertebrates. 
The “Melatonin Miracle” Is a Mirage 
A centerpiece of the so-called melatonin miracle sensa- 
tionalized in a recent pop science book is the claim that 
the hormone can reverse aging (Pierpaoli and Regelson, 
1995). This assertion is scientifically unfounded and is 
based on the results of a seriously flawed study performed 
in mice (Pierpaoli and Regelson, 1994). All the murine 
strains used in that study (BALB/c, C57BL/6, and NZB) 
have a well-described genetic defect in pineal melatonin 
biosynthesis and cannot make melatonin (Goto et al., 
1994, and references therein). Thus, any assertion that 
youthful pineal glands transplanted into old mice keep old 
mice from aging owing to restoration of “youthful” melato- 
nin levels is absurd. When these melatonin-deficient 
strains of mice were treated with pharmacological doses 
of melatonin, there was a 20% increase in life span in fe- 
male NZB and BALBlc mice, but not in female C57BL/6 
mice. However, these authors showed in another study 
(that is generally overlooked) that when comparable 
amounts of melatonin are given to a mouse strain (C3H/ 
He) that makes melatonin, the treatment actually short- 
ened survival by inducing reproductive tract tumors (refer- 
enced by Pierpaoli and Regelson, 1994). Thus, there is 
no evidence that melatonin administered to melatonin- 
producing mice can increase longevity. The evidence that 
melatonin can increase longevity in mice in general is in- 
consistent The suggestion that melatonin may increase 
longevity is humans is based purely on speculation. 
The antioxidant effect of melatonin has also been embel- 
lished, leading to claims that melatonin is a wonder drug 
useful for treating everything from AIDS to Alzheimer’s 
disease (Reiter and Robinson, 1995). Melatonin does act 
as an intracellular scavenger of hydroxyl and peroxyl free 
radicals when administered at pharmacological doses 
both in vivo and in vitro (reviewed by Reiter, 1995). Al- 
though the antioxidant potential of melatonin may have 
some therapeutic applications (although clearly not as 
many as claimed!), these antioxidant effects require mela- 
tonin concentrations about 106-fold greater than the physi- 
ological melatonin concentration (which is <l nM). Thus, 
the antioxidant effects of melatonin, being pharmacologi- 
cal, would not be expected to be mediated through physio- 
logically relevant high affinity receptors. To no great sur- 
prise, advocates of melatonin’s antioxidant abilities have 
embraced with open arms the unsubstantiated claims that 
melatonin may signal through low affinity nuclear recep- 
tors of the retinoid Z receptor family (Becker-Andre et al., 
1994; Wiesenberg et al., 1995). 
Melatonin Has Specific Neurobiological Effects 
Melatonin does have several bona fide biological effects 
that are mediated through high affinity receptors (Figure 
1). The most well-documented physiological role of mela- 
tonin is its regulation of seasonal responses to changes 
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Figure 1. Melatonln Acts through High Affinity G Protein-Coupled Re- 
ceptors to Elicit Its Physiological Effects 
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in day length in seasonally breeding mammals (reviewed 
by Arendt, 1995). These so-called photoperiodic re- 
sponses are dramatic and include changes in reproductive 
status, body weight, coat color, and behavior. By providing 
a measure of night length and thereby day length, the 
nocturnal secretory pattern of melatonin regulates these 
seasonal responses. 
Reproduction in humans may also be influenced bysea- 
son, but the effect is quite subtle (reviewed by Arendt, 
1995). Notably, preliminary reports have surfaced pro- 
claiming success in using a melatonin-progestin combina- 
tion as a contraceptive agent in humans. However, mas- 
sive amounts of melatonin (75-300 mg) are given in these 
preparations, leading to pharmacological effects of the 
hormone on other hormone regulatory systems (e.g., di- 
rect actions on estrogen receptors). This potential for inter- 
action with other systems should raise concern about the 
indiscriminate, unregulated use of melatonin in humans. 
Melatonin can entrain (set the timing of) mammalian 
circadian rhythms and appears to function in concert with 
light to hold circadian rhythms in phase with prevailing 
environmental conditions (Reppert et al., 1994, and refer- 
ences therein). Importantly, the entraining effect of mela- 
tonin on the biological clock is weak compared with the 
potent entraining effect of light. In a natural setting, en- 
trainment by melatonin may be most important during 
early development when retina-mediated light information 
cannot be processed (Davis and Mannion, 1988). In fact, 
during fetal life, at a time when the retina-SCN pathway 
has not yet formed, melatonin produced by the mother 
provides the developing SCN with entraining information. 
This maternal-fetal communication keeps the fetal clock 
entrained and in tune with the outside world until retina- 
mediated entrainment becomes functional during postna- 
tal life. 
Sound therapeutic applications of melatonin have been 
developed around its circadian effects (Arendt, 1995). Mel- 
atonin administered orally to humans has been used suc- 
cessfully to treat jet lag and some circadian-based sleep 
disorders. A critical feature of the circadian effect of mela- 
tonin is time of administration. Melatonin can alter circa- 
dian rhythms only during a restricted portion of the circa- 
dian cycle. 
Melatonin also has potent biological effects on the verte- 
brate retina (reviewed by Cahill and Besharse, 1995). 
Studies in Xenopus and chick reveal that melatonin is 
made rhythmically in the retina and acts locally to inhibit 
retinal dopamine release and to affect photopigment disc 
shedding and phagocytosis. Melatonin is also produced 
by the mammalian retina, and at physiological levels it 
inhibits Ca*+-dependent dopamine release in rabbit retina. 
Thus, melatonin may have several important regulatory 
functions in mammalian retina. 
The most recently described effect of melatonin for 
which there is good scientific evidence is its ability to in- 
duce sleep in humans. Importantly, the hypnotic effect 
occurs when very low levels of melatonin are administered 
(0.1-0.3 mg); daytime administration only increased se- 
rum melatonin levels to the normal nocturnal range (Dol- 
lins et al., 1994). This hypnotic effect appears to be separa- 
ble from melatonin’s effect on circadian rhythms and may 
occur through a thermoregulatory mechanism (see refer- 
ences in Dollins et al., 1994). 
The therapeutic potential of the hypnotic effects of mela- 
tonin is substantial. However, because of the time- 
sensitive activities of this hormone, clinical trials are 
clearly needed to identify the correct patient population 
and treatment regimens to optimize melatonin treatment. 
Unfortunately, melatonin’s hypnotic capability has also 
been embellished, serving as a catalyst in initiating the 
current media blitz. 
Melatonin Receptors Exist 
Over the past 8 years, radioreceptor assays and quantita- 
tive in vitro autoradiography using the potent melatonin 
agonist, 2-[‘251]iodomelatonin ([‘251]Mel), have identified 
high affinity melatonin receptors in a variety of vertebrate 
species, including humans (reviewed by Dubocovich, 
1995; see references in Reppert et al., 1994). These recep- 
tors have an equilibrium dissociation constant (Ko) of cl00 
pM. Their pharmacological specificity (rank order of inhi- 
bition of specific [1251]Mel binding) is 2-iodomelatonin > 
melatonin > 6chloromelatonin > 6-hydroxymelatonin > 
N-acetyl-5-hydroxytryptamine >> 5-HT. Receptor affinity 
is sensitive to guanine nucleotides, and activation of these 
receptors consistently leads to inhibition of adenylyl cy- 
clase through a pertussis toxin-sensitive mechanism. 
High affinity melatonin receptors thus appear to belong 
to the superfamily of guanine nucleotide-binding protein 
(G protein)-coupled receptors. 
In vitro autoradiography has localized high affinity mela- 
tonin receptors within individual brain nuclei and in a few 
nonneural sites. Significantly, these receptor sites appear 
to be the sites through which melatonin elicits its biological 
effects (reviewed by Dubocovich, 1995; Reppert et al., 
1994). In most mammals, high affinity melatonin receptors 
are found in the SCN; SCN receptors probably mediate 
the circadian effectsof melatonin. Receptors in the medio- 
basal hypothalamus of several photoperiodic rodents ap- 
pear to be involved in melatonin’s control of reproduction 
(Maywood and Hastings, 1995). Receptors in the inner 
plexiform layer of the retina may mediate melatonin’s ef- 
fects on retinal physiology. Melatonin receptors have been 
identified in the preoptic area, cerebral cortex, and thala- 
mus of some mammals, which could mediate the hypnotic 
effects of the hormone. 
Nonneural sites containing high affinity melatonin re- 
ceptors include the hypophyseal pars tuberalis, a site in- 
volved in the photoperiodic regulation of prolactin and per- 
haps in other photoperiodic responses (Lincoln and 
Clarke, 1994). High affinity melatonin receptors have also 
been identified in cerebral and caudal arteries, which may 
be involved in thermoregulatory function in rodents (see 
references in Dubocovich, 1995). 
A Family of Melatonin Receptors Is Cloned 
A major advance in understanding melatonin’sactions has 
been the recent cloning of a family of G protein-coupled 
receptors for melatonin. The strategy that succeeded in 
isolating the first melatonin receptor cDNA was expression 
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cloning (Ebisawa et al., 1994). The tissue source used for 
expression cloning took advantage of melatonin’s ability 
to cause melanin aggregation in dermal melanophores of 
amphibians. This action of melatonin is mediated by a high 
affinity receptor that iscoupled to inhibitory G,. Thus, using 
a cDNA library constructed from an immortalized cell line 
of Xenopus laevis dermal melanophores and a mamma- 
lian cell expression cloning strategy, a high affinity melato- 
nin receptor wascloned. The expressed recombinant Xen- 
opus receptor exhibits pharmacological and functional 
characteristics that are indistinguishable from those of en- 
dogenous receptors in amphibian dermal melanophores 
(Ebisawa et al., 1994). 
Structurally, the Xenopus receptor and related subtypes 
(see below) define a distinct receptor family within the 
large superfamily of G protein-coupled receptors (Figure 
2). The melatonin receptor proteins are not similar in iden- 
tity to any one particular group of G protein-coupled recep- 
tors, but are similar to a wide range of receptors within 
the G protein-coupled receptor superfamily (amino acid 
identity, - 25%). Distinguishing features of the melatonin 
receptor group include a NRY (rather than DRY or ERY) 
motif just downstream of the third transmembrane domain, 
a C(C/Y)ICHS motif immediately downstream of NRY, and 
a NAXXY (rather than NPXXY) motif in transmembrane 
domain 7 (Figure 2). 
Using a polymerase chain reaction (PCR) approach 
based on the frog sequence, a high affinity melatonin re- 
ceptor that was 60% identical at the amino acid level with 
the frog receptor was subsequently cloned from several 
mammals, including humans (Reppert et al., 1994). These 
mammalian receptors show >80% amino acid identity with 
each other and thus appear to be species homologs of 
the same receptor, designated the Mel,, melatonin recep- 
tor. The expressed recombinant mammalian receptors ex- 
hibit pharmacological and functional characteristics (e.g., 
coupling to G,) that are similar to their endogenous coun- 
terparts. The Melta receptor gene is expressed in the ro- 
dent SCN and pars tuberalis, prominent sites of [1251]Mel 
binding and the presumed sites of the circadian and some 
of the reproductive actions of melatonin, respectively. The 
Mel,, melatonin receptor may account for all the [r*51]Mel 
binding observed by in vitro autoradiography in mammals. 
However, extremely low levels of receptor mRNA expres- 
sion have precluded a firm determination as to whether 
the MeLa receptor is responsible for [‘251]Mel binding in 
some sites, such as blood vessels. The available evidence 
suggests that the Meha receptor is the receptor through 
which melatonin exerts its circadian and reproductive ac- 
tions in mammals. 
A second melatonin receptor, designated the MelIb re- 
ceptor, was recently cloned from humans (Reppert et al., 
1995a; Table 1). The human Mellb receptor is 60% identi- 
cal at the amino acid level to the human Meha receptor. 
The expressed Mellb receptor exhibits ligand binding char- 
acteristics that are very similar to those of the Mel,, recep- 
tor. The Mellb receptor is also coupled to inhibition of ade- 
nylyl cyclase. MelIb receptor mRNA is not detectable by 
in situ hybridization in the rat brain or pituitary, but reverse 
transcription (RT)-PCR shows that the Meltb receptor tran- 
script is expressed in human retina. The MelIb receptor 
may mediate the reported actions of melatonin in the mam- 
malian retina. 
The Mel,= and Mellb receptors are 60% identical at the 
amino acid level to each other, and each mammalian sub- 
type is 60% identical to the Xenopus receptor. Thus, it 
seemed possible that the frog receptor represents a third 
subtype. Indeed, molecular cloning studies in chickens 
identified a high affinity melatonin receptor that is 80% 
identical at the amino acid level with the frog receptor, 
but only 60% identical with the Meha and Meltb receptors 
(Reppert et al., 1995b). This subtype, designated the Mel,= 
receptor, has pharmacological and functional properties 
similar to the mammalian Mel,, and Mellb receptors (Table 
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Table 1. Characteristics of the G Protein-Coupled Melatonin 
Receptor Family 
Melatonin Receptor 
Subtypes K. (PM) Pharmacology CAMP 
Mel]. 20-40 I > M > 6 > N >> 5-HT Inhibit 
Meh 160 I > M = 6 > N >> 5-HT Inhibit 
MeL 20-60 I > M > 6 > N >> 5-HT Inhibit 
Ko determined using [1251]Mel as the ligand. Abbreviations: I, P-iode 
melatonin; M, melatonin; 6, Chydromelatonin; N, N-acetylShydroxytiyp 
tamine; 5-HT, 5-hydroxyttyptamine. 
1). PCR analysis of additional melatonin receptor frag- 
ments from Xenopus and zebrafish provided further evi- 
dence of three distinct melatonin receptor subtypes in ver- 
tebrates (Reppert et al., 1995b). A Mellc receptor has not 
yet been cloned in mammals. It is possible that mammals 
evolved without a Mellc receptor gene or that sequence 
divergence is too great for detection by PCR and library 
screening. This issue can only be clarified by further mo- 
lecular cloning studies. 
The three melatonin receptor subtypes have similar 
gene structure (Reppert et al., 1994, 1995a, 1995b). The 
portions of the genes that encode the receptor proteins 
are composed of two exons, separated by large (>8 kb) 
introns. The conserved position of the intron splice site in 
the DNA encoding the first cytoplasmic loop of all three 
receptors suggests that alternatively spliced forms may 
exist. The two human melatonin receptor genes reside 
on different chromosomes (Mel,, on 46135.1 and Mellb on 
llq21-22). 
Demystification of Melatonin 
Melatonin is a hormone. It has substantial biological ef- 
fects and signals through a family of G protein-coupled 
receptors. The therapeutic potential of this hormone is in 
the early stages of evaluation, with the most promising 
areas exploiting its circadian and hypnotic effects. 
Delineating melatonin receptor structure provides im- 
portant new tools for investigating fundamental mecha- 
nisms of melatonin action. For example, gene targeting 
can now be performed todetermine the precise physiologi- 
cal role(s) of each receptor subtype. Elucidating melatonin 
receptor gene structure may also allow a molecular means 
of accessing the biological clock in the SCN (e.g., targeted 
gene delivery). With recombinant melatonin receptors in 
hand, it should now be possible to identify highly specific 
agonists and antagonists that may be of therapeutic use 
in treating jet lag and circadian-based sleep disorders and 
of agricultural value in modulating the timing of reproduc- 
tion in seasonally breeding species. 
Rend Descartes, the French philosopher and mathema- 
tician, proclaimed in the 17th century that the pineal gland 
was the “seat of the soul.” Even Descartes would be aston- 
ished at the properties currently being attributed to melato- 
nin. Continued progress in understanding the cellular and 
molecular actions of melatonin will hopefully remove the 
mystery surrounding this hormone. The cure for melatonin 
madness is to ignore the hyperbole and histrionics and 
focus instead on hypothesis testing and sound science. 
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